<DOC>
	<DOCNO>NCT00844922</DOCNO>
	<brief_summary>Patients participate previous trial 28130 , eligible , entered trial . Patients randomize placebo previous trial 28130 continue placebo patient randomize Org 34517 ( SCH 900636 ) , regardless dose , titrate 900 mg Org 34517 . Patients trial take study medication 2 week order study safety tolerability Org 34517 .</brief_summary>
	<brief_title>Safety Org 34517 900 mg Patients Who Received Org 34517 Previous Trial ( Study 28133/P05842 )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>attend Screening , Baseline , Visit Day 15 , Day 29 Day 43 previous trial 28130 ; CGI Severity score 3 great Day 43 previous trial 28130 Day 1 current trial 28133 , low score investigator opinion resolution symptom warrant ; stable dose 'usual treatment ' , must consist antidepressant , antipsychotic , mood stabilizer combination 3 drug class . experience follow significant safety outcomes previous trial 28130 : severe breakthrough bleeding ; diagnosis prostatitis ; abnormal level testosterone Day 15 previous trial 28130 ; adverse event deem relevant exclusion trial 28133 investigator . abnormal PSA test Day 7 previous trial 28133 significant risk commit suicide , indicate score great 9 revised ISST Day 7 Day 1 ; currently treat carbamazepine valproate , midazolam , clozapine ; treat electroconvulsive therapy ( ECT ) current episode ; currently treat one antidepressant , antipsychotic , mood stabilizer ; 'usual treatment ' start discontinue 2 week Day 1 ; 'usual treatment ' dose change within one week prior Day 1 ; clinically unstable uncontrollable renal , hepatic , respiratory , hematological , cardiovascular cerebrovascular disease would put patient risk safety bias assessment efficacy ; know hypersensitivity reaction glucocorticoid antagonist ; clinically significant abnormal laboratory data ( e.g . aspartate amino transferase ( ASAT ) and/or alanine amino transferase ( ALAT ) value &gt; 2x normal range upper limit ) ECG result , clinically significant abnormal outcome physical examination Day 7 ; confirm positive result drug screen test illicit drug , except cannabis , Day 7 ; untreated uncompensated clinically significant endocrine disorder ; use hormone replacement therapy Day 7 ; require concomitant treatment corticosteroid ( topical use allow ) ; woman childbearing potential without adequate contraception woman positive pregnancy test Day 7 1 , breast feeding mother .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>